CRISPR Gene Editing Therapy Casgevy: From Proof of Concept to Clinical Success
In November 2023, the UK Medicines and Healthcare products Regulatory Agency (MHRA) approved the world's first CRISPR gene editing therapy, Casgevy (exa-cel), for the treatment of sickle cell disease and β-thalassemia. This marks not just the birth of a new drug, but a historic validation of a technology platform moving from the laboratory to the clinic.
The therapeutic mechanism of exa-cel is elegant and ingenious. Rather than directly repairing the defective hemoglobin gene, it edits the regulatory region of the BCL11A gene — a gene responsible in adults for shutting down fetal hemoglobin production. By making a precise cut at the correct location, Casgevy "reawakens" fetal hemoglobin expression, compensating for the functional deficiency of adult hemoglobin.
Clinical data is remarkable. In the trial for sickle cell disease, all 44 patients reached the primary endpoint — no vaso-occlusive crises occurred during the follow-up period. This is extremely rare in rare disease drug development. However, it should be noted that the sample size is limited (44 patients) and the maximum follow-up period is 24 months; durability still requires longer-term verification.
The commercial pricing of Casgevy ($2.2 million per course of treatment in the US) has sparked discussions about the accessibility of gene therapies. But from an industry perspective, what matters more is the improvement of delivery systems — exa-cel requires extracting hematopoietic stem cells from the patient, editing them ex vivo, and then infusing them back into the body. If in vivo direct delivery technology can be developed, the application scope of CRISPR therapies would expand from blood disorders to diseases of the liver, central nervous system, and other organs.